PROCEPT BioRobotics Q2 revenue up 97% to $16.7M; raises FY22 revenue guidance to $66-68M

PROCEPT BioRobotics Corp

2022-Q2 EPS reported -$0.82 revenue$30,888,000

Q2 2022 total revenue $16.7M, +97% YoY; U.S. system revenue $8.5M (+79%), handpiece and consumables $5.7M (+246%).
Net loss widened to $19.2M from $14.6M YoY; adjusted EBITDA loss $14.6M vs. $11.6M.
Raised FY22 revenue guidance to $66-68M (previous $58-62M); gross margin guidance raised to 50-51% from 47-49%.
U.S. Aquabeam system install base reached 114 systems as of June 30, 2022; gross margin improved to 51% from 42%.
Operating expenses $26.4M, up from $16.8M, driven by sales expansion and public company costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.